{"denoms":[{"counts":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"75"},{"groupId":"BG003","value":"219"}],"units":"Participants"}],"groups":[{"description":"Arm A Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3\n\nMethotrexate: Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.\n\nAra-C: Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses","id":"BG000","title":"MTX + AraC"},{"description":"Arm B Rituximab 375 mg/m2 conventional infusion d -5 \\& 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3\n\nMethotrexate: Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.\n\nAra-C: Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses\n\nRituximab: Rituximab 375 mg/m2 conventional infusion on day - 5 \\& 0 every 3 weeks for a maximum of 4 cycles","id":"BG001","title":"MTX + Ara-C + Rituximab"},{"description":"Arm C Rituximab 375 mg/m2 conventional infusion d -5 \\& 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3 Thiotepa 30 mg/m2 30 min. Infusion d 4\n\nMethotrexate: Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.\n\nAra-C: Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses\n\nRituximab: Rituximab 375 mg/m2 conventional infusion on day - 5 \\& 0 every 3 weeks for a maximum of 4 cycles\n\nThiotepa: ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 \\& -4","id":"BG002","title":"MTX + Ara-C + Rituximab+Thiotepa"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"75"},{"groupId":"BG003","value":"219"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"50","upperLimit":"64","value":"58"},{"groupId":"BG001","lowerLimit":"53","upperLimit":"63","value":"57"},{"groupId":"BG002","lowerLimit":"53","upperLimit":"62","value":"57"},{"groupId":"BG003","lowerLimit":"50","upperLimit":"64","value":"57"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"83"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"46"},{"groupId":"BG003","value":"136"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"11"}]}],"title":"Denmark"},{"categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"92"}]}],"title":"Italy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"39"}]}],"title":"United Kingdom"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}],"title":"Switzerland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"75"}]}],"title":"Germany"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"51"},{"groupId":"BG003","value":"145"}]}],"title":"ECOG 0-1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"74"}]}],"title":"ECOG>1"}],"description":"Patient's level of functioning in terms of their ability to care for themself, daily activity, and physical ability graded as follows:\n\n0\\. Fully active, able to carry on all pre-disease performance without restriction;\n\n1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature;\n2. Ambulatory and capable of all selfcare but unable to carry out any work activities;\n3. Capable of only limited selfcare;\n4. Completely disabled; totally confined to bed or chair;\n5. Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group Performance Status (ECOG-PS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"88"}],"title":"Increased LDH"},{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"131"}],"title":"No increased LDH"}]}],"description":"Increased serum lactate dehydrogenase concentration","paramType":"COUNT_OF_PARTICIPANTS","title":"Increased LDH","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"64"},{"groupId":"BG003","value":"174"}],"title":"Deep lesions"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"45"}],"title":"No deep lesions"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Deep lesions","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"101"}],"title":"Increased CSF protein"},{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"61"}],"title":"No increased CSF protein"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"57"}],"title":"Not recorded"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Increased cerebrospinal fluid (CSF) protein","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"39"}],"title":"Low Risk"},{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"47"},{"groupId":"BG003","value":"138"}],"title":"Intermediate Risk"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"42"}],"title":"High Risk"}]}],"description":"IELSG risk score is a widely used, 5-point prognostic model for primary central nervous system lymphoma (PCNSL) that predicts overall survival (OS) based on age (\\>60), performance status (ECOG \\>1), high serum LDH, high CSF protein, and deep brain involvement.\n\nLow risk: 80% 2 years OS; Intermediate risk: 48% 2 years OS; High risk: 15% 2 years OS.","paramType":"COUNT_OF_PARTICIPANTS","title":"International Extranodal Lymphoma Study Group (IELSG) risk score","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"7"}],"title":"Intraocular disease"},{"measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"74"},{"groupId":"BG003","value":"212"}],"title":"No intraocular disease"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Intraocular disease","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"34"}],"title":"Meningeal involvement"},{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"128"}],"title":"No meningeal involvement"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"57"}],"title":"Not recorded"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Meningeal involvement","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"41"},{"groupId":"BG003","value":"126"}],"title":"Multiple lesions"},{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"93"}],"title":"No multiple lesions"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Multiple lesions","unitOfMeasure":"Participants"}]}